Roche Expands Its Scope in Allogeneic Cell Therapy With $1B Poseida Therapeutics Acquisition
Roche is acquiring Poseida Therapeutics, a biotech developing allogeneic cell therapies for cancers and immunological indications. The two companies have been partners in hematological malignancies since 2022.